Biotech company VarmX has received clearance from the US FDA to begin a phase 3 trial of its lead candidate, VMX-C001, in ...

PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial evaluating PST-611, ...

The Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women ...

Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...

Cidara Therapeutics and hVIVO have announced encouraging topline results from a global phase 2b field study evaluating CD388, ...

Enhanced Genomics has appointed Dr Dietrich Stephan as Chair of the Board of Directors. In this role, Dietrich will guide ...

UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Why supporting representative trial participation matters ...

The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.

CLEO Systems is also part of the NHS Pathfinder pilot programme with around 200 community pharmacies in England, further ...

Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board. This move strengthens the Board as Clinigen advances its ...